Drug intelligence / Profile preview

ascorbic acid + pazopanib

Development stage: Unknown
Lead developer: Academic and Community Cancer Research United
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of high-dose intravenous ascorbic acid (Vitamin C) and pazopanib, a multi-tyrosine kinase inhibitor. This regimen is being investigated by the Academic and Community Cancer Research United (ACCRU) for the treatment of metastatic or unresectable clear cell renal cell carcinoma (ccRCC). Pazopanib acts by inhibiting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit, thereby blocking angiogenesis and tumor cell proliferation. Intravenous ascorbic acid is hypothesized to act as a pro-oxidant at high concentrations, generating hydrogen peroxide in the tumor microenvironment to induce oxidative stress and enhance the antitumor activity of pazopanib.

Brand names: Votrient
Other names: Vitamin C + PazopanibAscorbic Acid + Pazopanib Hydrochloride

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)

Beyond the preview

Go deeper on ascorbic acid + pazopanib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ascorbic acid + pazopanib.

Explore the full profile